ALX Oncology is laying off 30% of its staff, mainly in preclinical research, to redirect money toward clinical trials, ...
ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker evorpacept and planned entry into the clinic of its novel ...